<DOC>
	<DOCNO>NCT00281788</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , carboplatin , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together carboplatin , paclitaxel , radiation therapy treat patient esophageal cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Esophageal Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose capecitabine administer carboplatin , paclitaxel , radiotherapy patient carcinoma esophagus gastroesophageal junction . Secondary - Determine radiographic pathologic response rate patient treat regimen . - Correlate , preliminarily , tumor biomarker response clinical response patient treat regimen . OUTLINE : This open-label , dose-escalation study capecitabine . Patients undergo radiotherapy daily receive oral capecitabine twice daily day 1-5 carboplatin IV 30 minute paclitaxel IV 1 hour day 2 . Treatment repeat weekly 5 week absence disease progression unacceptable toxicity . Beginning week 9 ( 4 week complete chemoradiotherapy ) , patient may undergo surgery remove tumor . Patients unresectable gross residual disease complete radiotherapy may continue receive capecitabine , carboplatin , paclitaxel long chemotherapy beneficial . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma thoracic esophagus gastroesophageal junction bimodality treatment chemotherapy radiotherapy indicate No tumor extend level thoracic inlet beyond 4 cm gastroesophageal junction No esophageal perforation base radiographic bronchoscopic evidence No known brain metastasis , lymphangitic lung metastasis , carcinomatous meningitis PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 70 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 mg/dL Creatinine ≤ 1.5 time ULN Calcium ≤ 1.3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection serious underlie medical condition would preclude study treatment No dementia significantly alter mental status would preclude understand give informed consent PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>